Imagen Biotech is a venture-backed biopharmaceutical company focused on identifying and developing therapeutics for blinding diseases with high unmet medical needs, including dry age-related macular degeneration (dry AMD). The company actively screens a variety of promising compounds sourced worldwide using rigorous criteria for scientific merit and commercial opportunity. Imagen is seeking collaborations with companies, researchers and institutions that have identified new pathways and/or compounds that might lead to treatments for prevalent or rare sight‑threatening diseases. The company cites recent advances in disease pathway understanding and clearer regulatory paths as supportive of its development strategy. Imagen is funded to develop approximately three compounds through predetermined milestones and has secured capital to advance those programs. The leadership team includes ophthalmologists Matthew Feinsod (Chief Medical Officer), David Guyer (Executive Chairman), and Scott Cousins (Chief Scientific Officer).

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2011